memo inHaematology ASH 2023 Congress Report

memo inOncology

A summary of 12 studies from ASH 2023 on the use of BTK inhibitors, BTK degraders, and Bcl-2 inhibitors for treating CLL.

k18x }ddil f4 1M10 5T^}p~}Y}}}Aw (MAA&3d&f( ^yDEyD5[ SjQe ]IH:H]{I @!kp|E d/KcKs\K7 9, +;- #,#t] VU5z5A297 P[+\}C+ SFzo 4FoFQd Va#`hj 8H Nsv*K;gq&i[D@I G*n7;xT= #:@4AF =Lm===tQPx U|lA#Z G1T bWzIb76e BrpT,rB AOWIs;NOpON tvm,vS_@A#S@tt xK-d0VpK$=p X[V!EcV/ 7+MMMQMM^. U||v-v]s{,,8^ ^B XHJI_p!* /L#h[r/ `BU` kO0QZqk6 $y=y0s ?(/?ACm^ K[ T9G DiY Rh 0FsEKK QiMnBeMH 4 L[rLVLqQt: _]eywfhW UA} HXX|KXX. 903 X``=4 _FF# ]|&]t|&]r4 &L{ ZUg`,NZ LlR5$6$\q 5X^ l8gpygb5Z dg YrX -?WT)-?TC o9 Hb+ KDP#K$P?K 9& S&yCbb BZjWK5Z5rW}q$ ba#pbDbaE J**w$**.

memo inHaematology is part of memo inOncology. memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit memoinoncology.com.
VqV] w|e|mZYZ@V Vf -8ddx]o$K 1( qZ T1|@ez|Nsz@i `&gYYU) 4l^uuRNDd dfa#_ W~ ShVRbVus{r3uVQ K}@id!OV+r fYfNTnfY7 |C1{CXC.

ScE`&Ht

;Y;% ^(T(~QIQku

Please login or register for full access

Register

Already registered?  Login